These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

615 related items for PubMed ID: 10983738

  • 1. Clopidogrel: a review of its use in the prevention of atherothrombosis.
    Jarvis B, Simpson K.
    Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738
    [Abstract] [Full Text] [Related]

  • 2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    CAPRIE Steering Committee.
    Lancet; 1996 Nov 16; 348(9038):1329-39. PubMed ID: 8918275
    [Abstract] [Full Text] [Related]

  • 3. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
    Harker LA, Boissel JP, Pilgrim AJ, Gent M.
    Drug Saf; 1999 Oct 16; 21(4):325-35. PubMed ID: 10514023
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
    Hacke W.
    Cerebrovasc Dis; 2002 Oct 16; 13 Suppl 1():22-6. PubMed ID: 11803184
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Hankey GJ, Sudlow CL, Dunbabin DW.
    Cochrane Database Syst Rev; 2000 Oct 16; (2):CD001246. PubMed ID: 10796426
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence.
    Bogousslavsky J.
    Cerebrovasc Dis; 2001 Oct 16; 11 Suppl 2():5-10. PubMed ID: 11316916
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
    Montalescot G.
    Clin Cardiol; 2000 Nov 16; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
    [Abstract] [Full Text] [Related]

  • 14. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.
    Health Technol Assess; 2004 Oct 16; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clopidogrel for cerebrovascular prevention.
    Paciaroni M, Bogousslavsky J.
    Cerebrovasc Dis; 1999 Oct 16; 9(5):253-60. PubMed ID: 10473907
    [Abstract] [Full Text] [Related]

  • 19. Antiplatelet drugs in secondary prevention after acute myocardial infarction.
    Thizon-de-Gaulle I.
    Rev Port Cardiol; 1998 Dec 16; 17(12):993-7. PubMed ID: 9973860
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.